Profusa, Inc. (PFSA)
NASDAQ: PFSA · Real-Time Price · USD
0.3544
-0.0054 (-1.50%)
At close: May 29, 2026, 4:00 PM EDT
0.3649
+0.0105 (2.96%)
After-hours: May 29, 2026, 7:52 PM EDT
Profusa Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
1.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 100.00K | 55.00K | 122.22% |
| Dec 31, 2023 | 45.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 742.00K | -3.20M | -81.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nuwellis | 8.77M |
| INVO Fertility | 6.94M |
| Beyond Air | 6.92M |
| Intelligent Bio Solutions | 3.91M |
| ENvue Medical | 2.18M |
| Catheter Precision | 1.11M |
| iTonic Holdings | 523.03K |
| HeartSciences | 8.67K |
PFSA News
- 16 days ago - Profusa to transfer listing to Nasdaq - TheFly
- 16 days ago - Profusa Announces Listing Transfer to The Nasdaq Capital Market - GlobeNewsWire
- 23 days ago - Profusa receives favorable Nasdaq listing determination - TheFly
- 23 days ago - Profusa Receives Favorable Nasdaq Listing Determination - GlobeNewsWire
- 26 days ago - Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value - GlobeNewsWire
- 7 weeks ago - Profusa announces $30M letter of intent for PanOmics diagnostic platform - TheFly
- 7 weeks ago - Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform - GlobeNewsWire
- 3 months ago - Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering - GlobeNewsWire